Menu
Biolligence is revolutionizing the field of drug discovery by addressing one of the industry’s biggest challenges: accurately predicting human-specific drug toxicity. Traditional drug development heavily relies on animal models, which often fail to accurately translate to human outcomes. This results in high failure rates in clinical trials, costly delays, and prolonged time to market for life-saving treatments.
We help companies in their precision medicine design goals by predicting clinical toxicity at population scale
AI/ML enhances efficiency in drug discovery by automating tasks, analyzing vast datasets. predicting trends, and enabling smarter decision-making
iPSC technology enables precision toxicity testing by providing patient-specific cell models to evaluate drug safety and predict adverse effects with greater accuracy.
Our Generative AI accelerates drug discovery by designing novel, non-toxic molecules. we create optimized compounds with better safety profiles, reducing failures and speeding up market entry.
AI/ML enhances efficiency in drug discovery by automating tasks, analyzing vast datasets. predicting trends, and enabling smarter decision-making
iPSC technology enables precision toxicity testing by providing patient-specific cell models to evaluate drug safety and predict adverse effects with greater accuracy.
Our Generative AI accelerates drug discovery by designing novel, non-toxic molecules. we create optimized compounds with better safety profiles, reducing failures and speeding up market entry.
Empower your team with cutting-edge AI models, trained on diverse human-relevant data, to guide each stage of drug discovery with precision. With flexible subscription and pay-as-you-go options, Biolligence makes advanced toxicity prediction accessible and scalable, adapting to your project’s unique needs.